ACR Shares Acrux Limited
ASX · ASXLast in our picks 2026-10-22 — not in the current list; analysis below is from that screen
Transdermal drug portfolio and licensing potential provide a comparatively diversified biotech profile.
Signal breakdown
- ▸Portfolio commercialization and licensing optionality.
- ▸Above 50-day MA (+6.38%)
Is ACR a buy right now?
Trend: ACR is trading above the 50-day average (+0.00%), RSI 31 — neutral momentum, with a 3-month return of +0.00%.
Valuation & quality: Acrux Limited trades on forward P/E -0.3, PEG 0.42, price-to-book 3.33; fundamentals show net margin -9.2%, return on equity -48.5%, revenue growth 10.8% year on year.
Our screen: ACCUMULATE (score 1) — Transdermal drug portfolio and licensing potential provide a comparatively diversified biotech profile.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
Fundamentals
Technical signals
About Acrux Limited
Acrux Limited, together with its subsidiaries, develops and commercializes topically applied pharmaceutical products in Australia, the United States, Europe, and internationally.
Sector: Healthcare · Industry: Biotechnology · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.